Abstract
Editas Medicine and Allergan have begun a clinical trial of a CRISPR gene-editing therapy designed to remove a genetic mutation that causes a rare form of inherited blindness. The therapy, which is...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
